These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34908139)

  • 1. Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development.
    Lamtha T; Tabtimmai L; Bangphoomi K; Kiriwan D; Malik AA; Chaicumpa W; van Bergen En Henegouwen PMP; Choowongkomon K
    Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34908139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
    Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
    J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization.
    Najafi A; Valadan R; Asgarian-Omran H; Rafiei A; Tehrani M
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110999. PubMed ID: 37804659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and identification of anti-HER2 phage display single chain fragment of variable region library in human breast cancer].
    Lu XH; Wang ZW; Cai Y; Huang J; Zhu LH; Yang QL; Chen CJ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):434-40. PubMed ID: 25187458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant λ bacteriophage displaying nanobody towards third domain of HER-2 epitope inhibits proliferation of breast carcinoma SKBR-3 cell line.
    Shoae-Hassani A; Mortazavi-Tabatabaei SA; Sharif S; Madadi S; Rezaei-Khaligh H; Verdi J
    Arch Immunol Ther Exp (Warsz); 2013 Feb; 61(1):75-83. PubMed ID: 23224340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
    Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
    BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose
    Feng Y; Meshaw R; Zhao XG; Jannetti S; Vaidyanathan G; Zalutsky MR
    J Nucl Med; 2023 Jan; 64(1):124-130. PubMed ID: 35618478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
    Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
    Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer.
    Griffin N; Marsland M; Roselli S; Oldmeadow C; Attia J; Walker MM; Hondermarck H; Faulkner S
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32957504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an
    Feng Y; Meshaw R; McDougald D; Zhou Z; Zhao XG; Jannetti SA; Reiman RE; Pippen E; Marjoram R; Schaal JL; Vaidyanathan G; Zalutsky MR
    Sci Rep; 2022 Feb; 12(1):3020. PubMed ID: 35194100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
    Singla H; Munshi A
    Crit Rev Oncog; 2020; 25(3):241-250. PubMed ID: 33463944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development, High-Throughput Profiling, and Biopanning of a Large Phage Display Single-Domain Antibody Library.
    Lee HE; Cho AH; Hwang JH; Kim JW; Yang HR; Ryu T; Jung Y; Lee S
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732011
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Zhao L; Gong J; Qi Q; Liu C; Su H; Xing Y; Zhao J
    Int J Nanomedicine; 2023; 18():1915-1925. PubMed ID: 37064291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.
    Ding L; Tian C; Feng S; Fida G; Zhang C; Ma Y; Ai G; Achilefu S; Gu Y
    Theranostics; 2015; 5(4):378-98. PubMed ID: 25699098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.